Nexans reports Q3 revenue beat driven by Grids segment growth

Pharming experienced a stock price increase following a revenue beat in the third quarter. Simultaneously, Nexans reported a revenue beat for Q3, which was primarily driven by growth within its Grids segment. Both companies exceeded financial expectations for the period, resulting in positive market reactions for Pharming and strong segment performance for Nexans. These results highlight a period of financial growth and successful revenue generation for both entities during the third quarter of the year.